Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms VOLTAIRE-RA
- Sponsors Boehringer Ingelheim
- 27 Jul 2017 According to a Boehringer Ingelheim media release, results were presented at the annual European Congress of Rheumatology.
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 14 Jun 2017 Results published in a Boehringer Ingelheim media release.